Appointed to define strategies and deliver preclinical research support to the Global Oncology R&D head, head of Translational Medicine, and USA head of Academic Alliances. • Ensure strategic alignment between research and exploratory development • Initiate, maintain and optimize preclinical collaborations with academic and biotech partners • Evaluate therapeutic and technology opportunities for partnering, academic alliances, and venture capital • Represent Roche in academic collaborations on Joint Research Committees with leading academic cancer research centers• Lead platform-based biology efforts for added value to global oncology programs• Responsible for preclinical research study design and implementation, data evaluation, reporting and regulatory documentation • Represent the Oncology Disease Therapeutic Area (Oncology DTA) on the TCRC Leadership Team• Represent the TCRC site on the Global DTA Oncology Management Team

Led 12 scientists (3 Ph.D.) in preclinical in vivo pharmacology research in support of all Oncology projects, including small molecules, biologics, RNAi, and peptides.• Oversaw development of rodent models of cancer including subcutaneous and orthotopic xenografts from established solid or hematological cell lines, patient-derived xenografts, allografts, experimental metastasis and genetically engineered models, bioluminescence and fluorescence imaging• Led team for pharmacokinetic, antitumor efficacy and biomarker studies to support all site oncology projects• Contributed key data for the development of 10 clinical candidates • Contributed towards preclinical modeling of dose-dense regimen for capecitabine under clinical investigation for metastatic breast cancer• Project Leader for RO5486055, a humanized Hepsin neutralizing antibody for treatment of prostate and breast cancer reaching Clinical Lead stage • Member of Roche Global and Nutley Site Discovery Oncology Leadership Teams• Core member of Target Identification team with significant input into strategy and target selection• Contributed guidance and decision-making to Oncology portfolio, in-licensing opportunities (therapeutics or technologies) and department staffing• Represented preclinical tumor biology on early clinical development teams• Member of joint project teams with external partners• Initiated and managed academic collaborations and contract research• Managed internal and outsourcing budget for in vivo pharmacology studies and technology licensing • Authored and amended animal research protocols to support preclinical oncology research studies• 9 year member of Institutional Animal Care and Use Committee (Chair for 3 yrs)• Member of Roche Global Ethics Committee, with remit to review and approve all non-human primate studies